Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings

Core Viewpoint - Analysts project that Johnson & Johnson (JNJ) will report quarterly earnings of $2.77 per share, reflecting a 14.5% year-over-year increase, with revenues expected to reach $23.74 billion, a 5.6% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.3% higher over the last 30 days, indicating a collective reevaluation by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Sales Forecasts - Analysts forecast 'Sales- Innovative Medicine- WW' to reach $15.25 billion, indicating a 4.6% increase from the prior-year quarter [5]. - The consensus estimate for 'Sales- MedTech- Total' is $8.35 billion, reflecting a 5.8% increase year-over-year [5]. - 'Sales- Innovative Medicine- Neuroscience- WW' is expected to reach $2.06 billion, suggesting a 17.4% year-over-year change [5]. - 'Sales- MedTech- Orthopaedics- WW' is estimated at $2.23 billion, indicating a 1.7% increase from the year-ago quarter [6]. - 'Sales- Innovative Medicine- Oncology- CARVYKTI- WW' is projected to reach $515.54 million, reflecting an 80.3% year-over-year change [6]. - 'Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW' is expected at $430.12 million, indicating a 51.5% increase year-over-year [7]. - 'Sales- MedTech- Cardiovascular- Electrophysiology- WW' is projected to reach $1.42 billion, reflecting a 10.6% year-over-year change [7]. - 'Sales- MedTech- Cardiovascular- ABIOMED- WW' is expected to reach $436.24 million, indicating a 20.5% increase from the prior-year quarter [8]. - 'Sales- MedTech- Cardiovascular- Other Cardiovascular- WW' is projected at $101.04 million, reflecting a 5.3% year-over-year change [8]. - 'Sales- MedTech- Orthopaedics- Hips- US' is expected to reach $260.59 million, indicating a 4.2% year-over-year change [8]. - 'Sales- MedTech- Orthopaedics- Hips- International' is projected at $133.94 million, reflecting a 2.3% year-over-year change [9]. Organic Sales Growth - Analysts expect 'Organic Sales Growth (Operational growth)' to be 4.9%, compared to 6.3% reported in the same quarter last year [9]. Stock Performance - Shares of Johnson & Johnson have increased by 7.9% in the past month, outperforming the Zacks S&P 500 composite, which moved up by 4% [9].